Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window. We apologize for any inconvenience caused during this time.
Posted 04 February 2013 | By Ansis Helmanis,
China's State Food and Drug Administration (SFDA) issued a Notice on 29 January 2013 to provinces, municipalities and ports concerning the implementation of the national electronic monitoring system for imported pharmaceuticals, which will require foreign-based companies to have a local designate.
Foreign companies must designate a local Chinese pharmaceutical company, pharmaceutical wholesaler, subsidiaries or offices as their electronic monitoring agent in China. The local agent will be responsible for complying with the electronic monitoring requirements for the foreign company's imported drugs, and reporting to SFDA.
The requirement will take effect as of 31 December 2013. The notice includes links to the following registration forms:
Read all Breaking News from RegLink
Tags: SFDA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.